Clinical Trial Update: Study of Skin Toxicity of Cetuximab: Find a Link Between Skin Inflammation and Tumor Response [Phase 2]

View source ↗

Summary

Phase 2 trial update investigates whether skin toxicity from cetuximab correlates with tumor response in metastatic colorectal cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• ERBITUX (cetuximab)

Snippet

Sponsor: Poitiers University Hospital | Conditions: Metastatic Colon Cancer | Phase 2 | Status: COMPLETED